MarketPulse

ophthalmic diseases

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis Gears Up for Pivotal 2026 With Six Major Clinical Readouts Planned

Oculis announces investor conference participation ahead of landmark 2026 featuring multiple drug readouts and regulatory designations across three lead programs.
OCSOCSAWclinical trialsbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis Eyes Clinical Inflection Point With Six Pivotal Readouts Ahead

Oculis plans March 2026 investor conferences highlighting six pivotal clinical readouts, including Privosegtor's breakthrough optic neuritis program and OCS-01 Phase 3 results expected Q2 2026.
OCSOCSAWinvestor conferencesclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis Charts Bold 2026 Path With Pipeline Milestones at Investor Conferences

Oculis announces March 2026 investor conference participation, showcasing pipeline advances including Privosegtor's optic neuritis breakthrough designation and anticipated Phase 3 readouts.
OCSOCSAWinvestor conferencesclinical trials